

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/624,880	07/22/2003	Keith A. Webster	7230-4	1230
43463	63 7590 02/02/2006		EXAMINER	
RUDEN, MCCLOSKY, SMITH, SCHUSTER & RUSSELL, P.A. 222 LAKEVIEW AVE			SCHULTZ, JAMES	
SUITE 800	EW AVE		ART UNIT	PAPER NUMBER
WEST PALM	BEACH, FL 33401-6	5112	1635	

DATE MAILED: 02/02/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

•		Application No.	Applicant(s)		
Office Action Summary		10/624,880	WEBSTER, KEITH A.		
		Examiner	Art Unit		
		J. D. Schultz, Ph.D.	1635		
Period fo	The MAILING DATE of this communication apports Reply	pears on the cover sheet with the	correspondence address		
THE - Exte after - If the - If NC - Failt Any	ORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. nsions of time may be available under the provisions of 37 CFR 1.1 SIX (6) MONTHS from the mailing date of this communication. Period for reply specified above is less than thirty (30) days, a reply operiod for reply is specified above, the maximum statutory period or to reply within the set or extended period for reply will, by statute reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be tir y within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from , cause the application to become ABANDONE	mely filed  ys will be considered timely.  In the mailing date of this communication.  ED (35 U.S.C. § 133).		
Status					
1)🛛	Responsive to communication(s) filed on 14 D	ecember 2005.			
2a)□	This action is <b>FINAL</b> . 2b) ☐ This action is non-final.				
3)□	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.				
Disposit	ion of Claims				
_	Claim(s) is/are objected to.				
Applicat	ion Papers				
·	The specification is objected to by the Examine The drawing(s) filed on is/are: a) acc	epted or b)□ objected to by the			
11)	Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct The oath or declaration is objected to by the Ex	ion is required if the drawing(s) is ob	ejected to. See 37 CFR 1.121(d).		
			77.00.017 07.10117 70 102.		
12) a)i	Acknowledgment is made of a claim for foreign  All b) Some * c) None of:  1. Certified copies of the priority document  2. Certified copies of the priority document  3. Copies of the certified copies of the priority document  application from the International Bureau  See the attached detailed Office action for a list	s have been received. s have been received in Applicat rity documents have been receive u (PCT Rule 17.2(a)).	ion No ed in this National Stage		
Attachmen	• •	_			
2) 🔲 Notic 3) 🔲 Infor	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) r No(s)/Mail Date	4)			

Application/Control Number: 10/624,880 Page 2

Art Unit: 1635

## **DETAILED ACTION**

Upon further consideration and review of the claims, the previous restriction requirement mailed 15 November 2005 inadvertently failed to properly group the claim set. Accordingly, the instant restriction requirement supersedes the restriction mailed 15 November 2005 in its entirety.

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-4, drawn to a method for preventing or reducing hypoxia-acidosis induced injury to a cell comprising reducing BNIP3 mRNA in a cell, classified in class 514, subclass 44.
- II. Claims 1 and 5, drawn a method for preventing or reducing hypoxia-acidosis induced injury to a cell comprising to expressing a mutant BNIP3 protein function in a cell, classified in class 435, subclass 4.
- III. Claims 1 and 6, drawn to a method for preventing or reducing hypoxia-acidosis induced injury to a cell comprising preventing BNIP3 protein dimerization in a cell, classified in class 435, subclass 4.
- IV. Claims 1, and 7, drawn to a method for preventing or reducing hypoxia-acidosis induced injury to a cell comprising preventing translocation of BNIP3 protein to a mitochondrion in a cell, classified in class 435, subclass 4.
- V. Claims 1 and 8-10, drawn to a method for preventing or reducing hypoxiaacidosis induced injury to a cell comprising reducing BNIP3 expression or

activity by preventing or reversing acidosis in the cell, classified in class 435, subclass 4.

The inventions are distinct, each from the other because of the following reasons:

Inventions I through V are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are not disclosed as useful together, and have different modes of operation, because each Group requires a different effector molecule or process, which are unique to that group the. For example, Group I utilizes an antisense oligonucleotide not required by any other group, Group II requires a mutant BNIP3 protein not required by any other group, Group III utilizes a molecule which inhibits protein dimerization which requires a molecule that interferes with BNIP3 protein-protein interactions that is typically a small molecule and is not required by any other group, Group IV requires a molecule which prevents translocation of BNIP3 protein to mitochondrion which may comprise targeting any protein upstream or downstream of BNIP3 that is used in translocation and is not required by any other group, while Group V requires targeting upstream processes which give rise to acidosis in a cell which is not required by any other group. Furthermore, the search for multiple methods each of which have their own active steps and/or compounds in a single application constitutes a serious search burden on the office, because the searches are divergent and non-coextensive, and because of the large volume of literature which these multiple steps are expect to return. Restriction is proper therefore.

Art Unit: 1635

The element of claim 1 related to reducing activity of BNIP3 in a cell links inventions III, IV, and V. The restriction requirement among the linked inventions is subject to the nonallowance of the linking claim(s), claim 1. Upon the allowance of the linking claim(s), the restriction requirement as to the linked inventions shall be withdrawn and any claim(s) depending from or otherwise including all the limitations of the allowable linking claim(s) will be entitled to examination in the instant application. Applicant(s) are advised that if any such claim(s) depending from or including all the limitations of the allowable linking claim(s) is/are presented in a continuation or divisional application, the claims of the continuation or divisional application may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Where a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. In re Ziegler, 44 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

## Conclusion

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to J. Douglas Schultz, Ph.D. whose telephone number is 571-272-0763. The examiner can normally be reached on 8:00-4:30 M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Andrew Wang can be reached at 571-272-0811. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1635

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

JDS

J.D. SCHULTZ, Ph.D. PATENT EXAMINER